作者: Trapani, Jonathan B. ; Zuchowski, Yvonne ; Delpire, Eric ; Carty, Joshua S. ; Zhang, Mingzhi ; Harris, Raymond C. ; Zent, Roy ; Watts, Jason A. ; Arroyo, Juan Pablo ; Terker, Andrew S. ; Bock, Fabian

Hypothalamic vasopressin is required for appropriate urinary concentration. However, whether collecting duct-derived vasopressin is involved remains unknown. We developed a novel transgenic mouse model to induce tissue-specific deletion of vasopressin and showed that collecting duct-derived vasopressin is not required to concentrate or dilute urine.

2023-06-01·American Journal of Physiology-Renal Physiology

Insulin-regulated aminopeptidase is required for water excretion in response to acute hypotonic stress

Article

作者: Zuchowski, Yvonne ; Bhave, Gautam ; Carty, Joshua ; Keller, Susanna ; Harris, Raymond C. ; Watts, Jason A. ; Trapani, Jonathan B. ; Arroyo, Juan Pablo ; Bock, Fabian ; Zhang, Mingzhi ; Zent, Roy ; Terker, Andrew S.

Insulin-regulated aminopeptidase (IRAP) degrades vasopressin, but its role in urinary concentration and dilution is unknown. Here, we show that IRAP-deficient mice have a high urinary osmolality at baseline and are unable to excrete free water in response to water loading. These results reveal a novel regulatory role for IRAP in urine concentration and dilution.

2023-01-01·Toxicology Letters

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

Article

作者: Naisbitt, Dean J ; Meng, Xiaoli ; Hammond, Sean ; Mosedale, Merrie

Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients. An important clinical conundrum following the contraindication of tolvaptan is whether administration of agents of similar pharmacological action and structure will be tolerated. Herein, we addressed this question through the exposure of tolvaptan-responsive T-cell clones to similar pharmaceutical agents. Whilst lixivaptan and conivaptan did not activate tolvaptan-responsive T-cells, mozavaptan evoked proliferative responses comparable with tolvaptan itself, indicating that there may be collateral immunological intolerance to this compound as a product of sensitization to tolvaptan.

100 项与盐酸莫扎伐普坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01855	盐酸莫扎伐普坦	C03XA	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
低钠血症	日本	Otsuka Holdings Co., Ltd.	2006-07-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血压	临床2期	日本	Otsuka Pharmaceutical Co., Ltd.	-
多囊肾	临床2期	美国	-	-
心肌梗塞后综合征	临床2期	日本	Otsuka Pharmaceutical Co., Ltd.	-